Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
colorectal cancer
Biotech
Merck's LAG-3 combo fails colorectal cancer phase 3 study
The fixed-dose combination failed to improve overall survival, extending the wait for a checkpoint inhibitor that moves the needle in the indication.
Nick Paul Taylor
Sep 25, 2024 8:35am
ESMO: Innovent links cytokine to colorectal cancer responses
Sep 18, 2024 9:53am
Exact Sciences presents early colorectal cancer blood test data
Sep 16, 2024 11:30am
Another of NuCana's retooled chemotherapies struggles in clinic
Aug 30, 2024 7:50am
FDA approves Guardant’s colorectal cancer screening blood test
Jul 29, 2024 11:00am
FDA wrecks Agenus’ accelerated approval plan
Jul 18, 2024 8:01am